Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 307


Knockdown of Heparanase Suppresses Invasion of Human Trophoblasts by Activating p38 MAPK Signaling Pathway.

Che G, Wang Y, Zhou B, Gao L, Wang T, Yuan F, Zhang L.

Dis Markers. 2018 Apr 17;2018:7413027. doi: 10.1155/2018/7413027. eCollection 2018.


Heparanase expression in blood is sensitive to monitor response to anticancer treatment in pancreatic cancer, a pilot study.

Wu W, Zhao L, Yu Y, Hu H, Shi H, Jia Q, Du L.

Pancreatology. 2018 Jan;18(1):100-105. doi: 10.1016/j.pan.2017.11.004. Epub 2017 Nov 13.


Heparanase level and procoagulant activity are reduced in severe sepsis.

Matan M, King D, Peled E, Ackerman S, Bar-Lavi Y, Brenner B, Nadir Y.

Eur J Haematol. 2018 Feb;100(2):182-188. doi: 10.1111/ejh.12997. Epub 2017 Dec 1.


Plasma heparanase is associated with blood glucose levels but not urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.

Zhao Y, Liu J, Ten S, Zhang J, Yuan Y, Yu J, An X.

Ren Fail. 2017 Nov;39(1):698-701. doi: 10.1080/0886022X.2017.1384391.


Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data.

Sun X, Zhang G, Nian J, Yu M, Chen S, Zhang Y, Yang G, Yang L, Cheng P, Yan C, Ma Y, Meng H, Wang X, Li JP.

Oncotarget. 2017 Jun 27;8(26):43521-43535. doi: 10.18632/oncotarget.16575. Review.


The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target.

Khamaysi I, Singh P, Nasser S, Awad H, Chowers Y, Sabo E, Hammond E, Gralnek I, Minkov I, Noseda A, Ilan N, Vlodavsky I, Abassi Z.

Sci Rep. 2017 Apr 6;7(1):715. doi: 10.1038/s41598-017-00715-6.


Heparanase augments insulin receptor signaling in breast carcinoma.

Goldberg R, Sonnenblick A, Hermano E, Hamburger T, Meirovitz A, Peretz T, Elkin M.

Oncotarget. 2017 Mar 21;8(12):19403-19412. doi: 10.18632/oncotarget.14292.


Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site.

Bohdan N, Espín S, Águila S, Teruel-Montoya R, Vicente V, Corral J, Martínez-Martínez I.

PLoS One. 2016 Jun 20;11(6):e0157834. doi: 10.1371/journal.pone.0157834. eCollection 2016.


Novel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells.

Song Y, Hu B, Qu H, Wang L, Zhang Y, Tao J, Cui J.

Oncotarget. 2016 Jun 14;7(24):36154-36167. doi: 10.18632/oncotarget.8959.


Increased Granulocyte Heparanase Activity in Neutrophils from Patients with Lupus Nephritis and Idiopathic Membranous Nephropathy.

Szymczak M, Kuźniar J, Kopeć W, Żabińska M, Marchewka Z, Kościelska-Kasprzak K, Klinger M.

Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):83-91. doi: 10.1007/s00005-016-0396-8. Epub 2016 Apr 18.


Heparanase procoagulant activity in cancer progression.

Nadir Y, Brenner B.

Thromb Res. 2016 Apr;140 Suppl 1:S44-8. doi: 10.1016/S0049-3848(16)30097-4. Review.


Heparanase procoagulant activity as a predictor of wound necrosis following diabetic foot amputation.

Peled E, Melamed E, Portal TB, Axelman E, Norman D, Brenner B, Nadir Y.

Thromb Res. 2016 Mar;139:148-53. doi: 10.1016/j.thromres.2016.01.014. Epub 2016 Jan 24.


Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.

Li J, Pan Q, Rowan PD, Trotter TN, Peker D, Regal KM, Javed A, Suva LJ, Yang Y.

Oncotarget. 2016 Mar 8;7(10):11299-309. doi: 10.18632/oncotarget.7170.


Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: a Meta- analysis.

Li HL, Gu J, Wu JJ, Ma CL, Yang YL, Wang HP, Wang J, Wang Y, Chen C, Wu HY.

Asian Pac J Cancer Prev. 2015;16(18):8653-8.


Upregulated Expression of Heparanase in the Vitreous of Patients With Proliferative Diabetic Retinopathy Originates From Activated Endothelial Cells and Leukocytes.

Abu El-Asrar AM, Alam K, Nawaz MI, Mohammad G, Van den Eynde K, Siddiquei MM, Mousa A, De Hertogh G, Geboes K, Opdenakker G.

Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8239-47. doi: 10.1167/iovs.15-18025.


Heparanase augments inflammatory chemokine production from colorectal carcinoma cell lines.

Tsunekawa N, Higashi N, Kogane Y, Waki M, Shida H, Nishimura Y, Adachi H, Nakajima M, Irimura T.

Biochem Biophys Res Commun. 2016 Jan 22;469(4):878-83. doi: 10.1016/j.bbrc.2015.12.074. Epub 2015 Dec 20.


Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.

Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD.

Oncotarget. 2016 Jan 12;7(2):1598-607. doi: 10.18632/oncotarget.6408.


Structural characterization of human heparanase reveals insights into substrate recognition.

Wu L, Viola CM, Brzozowski AM, Davies GJ.

Nat Struct Mol Biol. 2015 Dec;22(12):1016-22. doi: 10.1038/nsmb.3136. Epub 2015 Nov 16. Erratum in: Nat Struct Mol Biol. 2016 Jan;23(1):91.


Recent data concerning heparanase: focus on fibrosis, inflammation and cancer.

Secchi MF, Masola V, Zaza G, Lupo A, Gambaro G, Onisto M.

Biomol Concepts. 2015 Dec;6(5-6):415-21. doi: 10.1515/bmc-2015-0021. Review.


Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G.

Nat Med. 2015 May;21(5):524-9. doi: 10.1038/nm.3833. Epub 2015 Apr 13.

Supplemental Content

Support Center